Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL. 6, 2008, Pages 145-152

  Brajer, B ^a,b   Batura Gabryel, H ^a   Nowicka, A ^a   Kuznar Kaminska, B ^a   Szczepanik, A ^b  

^a Department of Pulmonary Diseases ^*  (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Airway obstruction; Chronic obstructive pulmonary disease; Serum metalloproteinases 9

Indexed keywords

GELATINASE B; SALBUTAMOL; BIOLOGICAL MARKER;

AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED EXPIRATORY VOLUME; LUNG FUNCTION; SMOKING; SPIROMETRY; STATISTICAL SIGNIFICANCE; BLOOD; ENZYMOLOGY; FEMALE; HUMAN; LUNG FUNCTION TEST; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; VITAL CAPACITY;

AIRWAY OBSTRUCTION; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SMOKING; VITAL CAPACITY;

EID: 64549091041     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD 2007).
2. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-688.
3. Mroz RM, Noparlik J, Chyczewska E, Braszko JJ, Holownia A. Molecular basis of chronic inflammation in lung diseases: new therapeutic approach. J Physiol Pharmacol 2007; 58 Suppl 5: 453-460.
4. Mroz RM, Holownia A, Chyczewska E et al. Cytoplasm-nuclear trafficking of CREB and Creb phosphorylation at SER133 during therapy of chronic obstructive pulmonary disease. J Physiol Pharmacol 2007; 58 Suppl 5: 437-444.
5. Belvisi MG, Bottomley KM. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): the therapeutic role for inhibitors of MMPs? Inflamm Res 2003; 52: 95-100.
6. Vignola AM, Paganin F, Capieu L et al. Airway remodeling assesses by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J 2004; 24: 910-917.
7. Vernooy JHJ, Liendeman JHN, Jacobs JA, Hanemaaier R, Wouters EFM. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinse-9 in induced sputum from patients with COPD. Chest 2004; 126: 1802-1810.
8. Montano M, Beccerril C, Ruiz V, Ramos C, Sansores RH, Gonzalez-Avilaa G. Matrix metalloproteinases activity in COPD associated with wood smoke. Chest 2004; 125: 466-472.
9. Quanjer PH. Standarized lung function testing. Report of Working Party for the European Community for Steel and Coal. Bull Eur Physiopath Respir 1983; 19: 22-27.
10. Sherril DL, Lebowitz MD, Knudson RJ, Burrows B. Continuous longitudinal regression equations for pulmonary function measures. Eur Respir J 1992; 5: 452-462.
11. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-2154.
12. Shapiro SD. Matrix metalloproteinases degradation of extracellular matrix; Biological consequences. Curr Opin Cell Biol 1998; 10: 602-608.
13. Cataldo D, Munaut C, Noel A et al. MMP-2 and MMP-9 linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2000; 123: 259-267.
14. Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003; 97: 634-639.
15. Russel RE, Culpitt SV, DeMatos C et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1990; 159: 596-602.
16. Vignola AM, Riccobono L, Mirabella A et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airway obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158: 1945-1950.
17. Culpitt SV, Rogers DF, Travers SL, Barnes PJ, Donnelly LE. Sputum matrix metalloproteinases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005; 99: 703-710.
18. Kang MJ, Oh JM, Lee JCh et al. Lung matrix metalloproteinase-9 correlates with cigarette smoking and obstruction of airflow. J Korean Med Sci 2003; 18: 821-827.
19. Seruga-Valdez L, Pardo A, Gaxiola M et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchyma cell health in COPD. Chest 2000; 117: 684-694.
20. Man SFP, Sin DD. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 78-82.
21. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128: 2099-2107.
22. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 367-370.
23. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257.
24. Higashimoto Y, Yamagata Y, Iwata T et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J 2005; 25: 885-890.
25. Cataldo D, Munaut C, Noel A et al. Matrix metalloproteinases and TIMP-1 production by peripheral blood granulocytes from COPD patients and asthmatics. Allergy 2001; 56: 145-151.
26. Aldonyte R, Jansson L, Piitulainen E, Janciauskiene S. Circulating monocytes from healthy individuals and COPD patients. Respir Res 2003; 4: 11.
27. Mao JT, Tashkin DP, Belloni PN, Baileyhealy I, Baratelli F, Roth MD. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase- 1 in patients with emphysema. Chest 2003; 124: 1724-1732.